Patricia L Allen
CIK 1348587 · Chief Financial Officer · last filed 2026-06-17
Patricia L Allen is a Chief Financial Officer who has filed 32 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for ZBIO, was dated Jun 17, 2026. Across all open-market trades the lifetime net is −$2.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $7.1M across reported positions. 9 SEC filings were submitted jointly with ALNYLAM PHARMACEUTICALS, INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$7.12M
5
32
-$2.88M
Filer Profile
200 SMITH STREET
WALTHAM, MA 02451
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZBIO | Director | 19,860 | $31.12 | $618.0K | $499.7K | 4 | 2026-06-17 |
| Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Director | 0 | $25.59 | $0 | -$2.34M | 13 | 2024-06-11 |
| KINETA, INC./DE (YMTX) Delisted | Director | — | $13.23 | — | $0 | 2 | 2021-06-04 |
| Larimar Therapeutics, Inc. (ZFGN) Delisted | Chief Financial Officer | 1,649 | — | — | $49.9K | 6 | 2019-01-24 |
| ALNY | VP of Finance and Treasurer | 26,165 | $248.68 | $6.51M | -$1.08M | 7 | 2010-12-10 |
Recent Filings
32 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-17 | ZBIO | Grant (A) | — | $0 | EDGAR |
| 2026-02-13 | ZBIO | Buy (P) | +19,860 | $499.7K | EDGAR |
| 2025-06-12 | ZBIO | Grant (A) | — | $0 | EDGAR |
| 2024-09-16 | ZBIO | Grant (A) | — | $0 | EDGAR |
| 2024-06-11 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Disp (D) | — | $0 | EDGAR |
| 2024-01-18 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-23 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-01-19 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-24 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-01-20 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.